title: Valsartan in the treatment of hypertension.
abstract: BACKGROUND
  Hypertension represents an important public health problem. Effective treatment of hypertension is imperative for primary care.
  
  
  OBJECTIVE
  The goal of this study was to examine the efficacy of Valsartan in the treatment of hypertension with emphasis on the overall efficacy in reduction of systolic and diastolic blood pressure in a sample of 738 patients.
  
  
  METHODS
  The study lasted for 12 months (from January 1, 2012 until December 31, 2012 year) and conducted in 18 public health institutions in B&H. Parallel follow up of Valsartan antihypertensive effect through repeated measurements every three months was conducted.
  
  
  CONCLUSIONS
  Our results indicate that both systolic and diastolic blood pressure decreased significantly after 12 weeks of Valsartan treatment. Analysis of adverse effects did not showed statistical significance of side effects for total sample. Statistical analysis by Yates chi-square did not show the presence of statistically significant differences in adverse effects by gender.
  
  
  CONCLUSIONS
  We conclude that Val or Val plus are effective and safe antihypertensive drugs for the treatment of mild to moderate
authors.affiliation: Cantonal Hospital Zenica, Bosnia and Herzegovina.
authors.forename: Salem
authors.initials: S
authors.lastname: Alajbegovic
authors.forename: Aziz
authors.initials: A
authors.lastname: Sukalo
authors.forename: Azra
authors.initials: A
authors.lastname: Alajbegovic
authors.forename: Jasminka Djelilovic
authors.initials: JD
authors.lastname: Vranic
authors.forename: Melika
authors.initials: M
authors.lastname: Ambeskovic
authors.forename: Dervis
authors.initials: D
authors.lastname: Deljo
authors.forename: Lejla
authors.initials: L
authors.lastname: Alajbegovic
mesh_terms: D000328:Adult; D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013777:Tetrazoles / Q000627:therapeutic use*; D016896:Treatment Outcome; D014633:Valine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068756:Valsartan; D055815:Young Adult
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D013777:Tetrazoles; D000068756:Valsartan; D014633:Valine